MCID: ECL001
MIFTS: 52

Eclampsia

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Eclampsia

MalaCards integrated aliases for Eclampsia:

Name: Eclampsia 11 19 28 53 43 14 71 75 31 33
Eclampsia in Puerperium 11 71
Postpartum Eclampsia 11 33
Eclampsia, Postpartum 11
Puerperal Eclampsia 33

Classifications:



External Ids:

Disease Ontology 11 DOID:13593
MeSH 43 D004461
NCIt 49 C87167
SNOMED-CT 68 156111007
ICD10 31 O15 O15.2
UMLS 71 C0013537 C0156678

Summaries for Eclampsia

GARD: 19 A potentially life-threatening pregnancy-related disorder characterized by tonic-clonic seizures in association with hypertension after the twentieth week of gestation and up to six weeks postpartum and in the absence of other potential causes of seizures.

MalaCards based summary: Eclampsia, also known as eclampsia in puerperium, is related to preeclampsia/eclampsia 1 and severe pre-eclampsia, and has symptoms including seizures An important gene associated with Eclampsia is STOX1 (Storkhead Box 1), and among its related pathways/superpathways are VEGFR1 specific signals and S1P3 pathway. The drugs Azithromycin and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, placenta and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology: 11 A pre-eclampsia characterized by the presence of seizures.

Wikipedia: 75 Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia. Pre-eclampsia is one of... more...

Related Diseases for Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 695)
# Related Disease Score Top Affiliating Genes
1 preeclampsia/eclampsia 1 32.4 SERPINC1 PEE1
2 severe pre-eclampsia 31.9 VEGFA STOX1 SERPINC1 PGF PAPPA OXT
3 mild pre-eclampsia 31.8 VEGFA SERPINC1 PGF PAPPA OXT FLT1
4 hellp syndrome 31.8 VEGFA THBD SERPINC1 PGF MTHFR FLT1
5 hypertensive encephalopathy 31.0 VEGFA PGF FLT1 ACE
6 gestational trophoblastic neoplasm 30.8 PGF PAPPA OXT
7 pulmonary edema 30.7 SERPINC1 OXT ACE
8 antiphospholipid syndrome 30.7 THBD SERPINC1 PGF MTHFR
9 placental abruption 30.6 SERPINC1 PGF PAPPA OXT MTHFR FLT1
10 thrombophilia 30.6 THBD SERPINC1 MTHFR ACE
11 persistent fetal circulation syndrome 30.6 VEGFA PGF OXT HLA-G
12 pregnancy loss, recurrent 1 30.6 MTHFR HLA-G
13 patau syndrome 30.6 STOX1 PGF PAPPA
14 kidney disease 30.5 VEGFA THBD PAPPA MTHFR ENG ACE
15 placental insufficiency 30.5 VEGFA SERPINC1 PGF PAPPA FLT1 ENG
16 hypertensive retinopathy 30.5 VEGFA ACE
17 chorioamnionitis 30.5 VEGFA OXT FLT1
18 thrombophilia due to thrombin defect 30.4 THBD SERPINC1 MTHFR
19 vascular disease 30.4 VEGFA THBD SERPINC1 MTHFR ENG ACE
20 microvascular complications of diabetes 5 30.3 VEGFA PGF FLT1 ACE
21 exudative vitreoretinopathy 1 30.3 VEGFA PGF FLT1
22 thrombophilia due to activated protein c resistance 30.3 THBD SERPINC1 MTHFR
23 retinal vascular disease 30.3 VEGFA PGF FLT1 ACE
24 stroke, ischemic 30.2 VEGFA THBD SERPINC1 MTHFR ENG ACE
25 hyperhomocysteinemia 30.2 THBD SERPINC1 MTHFR
26 deficiency anemia 30.2 VEGFA SERPINC1 OXT ENG ACE
27 respiratory failure 30.2 VEGFA THBD SERPINC1 ACE
28 placenta praevia 30.2 PGF PAPPA OXT
29 oligohydramnios 30.2 PGF PAPPA OXT ACE
30 vascular dementia 30.1 VEGFA MTHFR ACE
31 migraine with or without aura 1 30.1 VEGFA OXT MTHFR ACE
32 pulmonary hypertension 30.0 VEGFA THBD PGF FLT1 ENG ACE
33 retinal vein occlusion 30.0 VEGFA SERPINC1 MTHFR ACE
34 preterm premature rupture of the membranes 30.0 PGF PAPPA OXT
35 papilledema 30.0 VEGFA SERPINC1 ACE
36 carotid stenosis 30.0 VEGFA MTHFR ACE
37 ischemia 29.9 VEGFA PGF FLT1 ACE
38 cerebral palsy 29.9 THBD SERPINC1 OXT MTHFR
39 patent ductus arteriosus 1 29.9 VEGFA MTHFR ACE
40 protein s deficiency 29.9 THBD SERPINC1 MTHFR
41 protein c deficiency 29.9 THBD SERPINC1 MTHFR
42 twin-to-twin transfusion syndrome 29.9 PGF PAPPA FLT1 ENG
43 hypertension, essential 29.8 VEGFA THBD SERPINC1 PGF PAPPA OXT
44 pre-eclampsia 29.8 VEGFA THBD TAC3 STOX1 SERPINC1 PGF
45 ovarian hyperstimulation syndrome 29.7 VEGFA SERPINC1 FLT1
46 sagittal sinus thrombosis 29.7 SERPINC1 MTHFR
47 malaria 29.7 VEGFA THBD SERPINC1 FLT1 ENG ACE
48 intracranial hypotension 29.6 SERPINC1 MTHFR
49 portal vein thrombosis 29.6 THBD SERPINC1 MTHFR
50 heart disease 29.6 VEGFA THBD SERPINC1 PGF MTHFR FLT1

Graphical network of the top 20 diseases related to Eclampsia:



Diseases related to Eclampsia

Symptoms & Phenotypes for Eclampsia

UMLS symptoms related to Eclampsia:


seizures

MGI Mouse Phenotypes related to Eclampsia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ACE CORIN ENG EPHX1 FLT1 HLA-G
2 growth/size/body region MP:0005378 10 ACE CORIN ENG FLT1 HLA-G INHBB
3 renal/urinary system MP:0005367 9.92 ACE CORIN ENG OXT SERPINC1 STOX1
4 cardiovascular system MP:0005385 9.77 ACE CORIN ENG FLT1 HLA-G NOSTRIN
5 reproductive system MP:0005389 9.36 ACE FLT1 INHBB MTHFR OXT PAPPA

Drugs & Therapeutics for Eclampsia

Drugs for Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
6
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
7
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
8
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
9
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
10
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
11
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
12
Captopril Approved Phase 4 62571-86-2 44093
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
18
Labetalol Approved Phase 4 36894-69-6 3869
19
Ibuprofen Approved Phase 4 15687-27-1 3672
20
Nifedipine Approved Phase 4 21829-25-4 4485
21
Metamizole Approved, Investigational, Withdrawn Phase 4 50567-35-6 3111 522325
22
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
23
Phenylephrine Approved Phase 4 59-42-7 6041
24
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
25
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
26
Vitamin D2 Phase 4 3249
27 Ergocalciferols Phase 4
28 Anti-Bacterial Agents Phase 4
29 Anti-Arrhythmia Agents Phase 4
30 Sympatholytics Phase 4
31 Estrogens Phase 4
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4
33 Pharmaceutical Solutions Phase 4
34 Hormone Antagonists Phase 4
35 Estrogen Receptor Antagonists Phase 4
36 Estrogen Antagonists Phase 4
37 17 alpha-Hydroxyprogesterone Caproate Phase 4
38 11-hydroxyprogesterone Phase 4
39 Caproate Phase 4
40 Progestins Phase 4
41 Isosorbide-5-mononitrate Phase 4
42 Sodium Channel Blockers Phase 4
43 Anesthetics, Local Phase 4
44 Diuretics, Potassium Sparing Phase 4
45 Hypoglycemic Agents Phase 4
46 Narcotics Phase 4
47 diuretics Phase 4
48 Hydrochlorothiazide, lisinopril drug combination Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Adrenergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 630)
# Name Status NCT ID Phase Drugs
1 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
2 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
3 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
4 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Unknown status NCT03233880 Phase 4 Azithromycin 1gm
5 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
6 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
7 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
8 A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort Unknown status NCT04631627 Phase 4 Aspirin
9 Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy Unknown status NCT03237000 Phase 4 MgSO4
10 Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial Unknown status NCT04051567 Phase 4 Aspirin 100mg
11 Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial) Unknown status NCT00117546 Phase 4 alpha methyldopa
12 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Unknown status NCT03449277 Phase 4 Oral Tablet
13 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
14 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
15 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
16 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
17 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
18 A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
19 Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
20 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
21 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
22 A Randomized Controlled Trial Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Completed NCT04236258 Phase 4 NIFEdipine ER;Enalapril
23 Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study Completed NCT04077853 Phase 4 17 Hydroxyprogesterone Capronate
24 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
25 Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia Completed NCT03171480 Phase 4 Monoket Pill;Placebo
26 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
27 Comparison Between Different Norepinephrine Bolus Doses for Management of Post-spinal Hypotension During Ceaserian Section for Patients With Preeclampsia Completed NCT05368415 Phase 4 Norepinephrine
28 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
29 Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients Completed NCT03506724 Phase 4 Nifedipine;Labetalol
30 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
31 Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women Completed NCT02835339 Phase 4 Magnesium sulfate 4g loading dose, 1g/hr infusion;Magnesium sulfate 6g loading dose, 2g/hr infusion
32 Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study Recruiting NCT04908982 Phase 4 Aspirin 81mg
33 Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
34 Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial Recruiting NCT04441073 Phase 4 Lignocaine;Placebo
35 Effect of Non-steroidal Anti-inflammatory Use on Blood Pressure in Women With Hypertensive Disorders of Pregnancy: A Randomized Open Label Trial Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
36 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
37 162 mg of Aspirin for Prevention of Preeclampsia Recruiting NCT05221164 Phase 4 Aspirin 162 mg
38 Aspirin to Prevent Cardiac Dysfunction in Preeclampsia Recruiting NCT04479072 Phase 4 Aspirin 81 mg;Placebo
39 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Recruiting NCT03570632 Phase 4 Metformin
40 Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia Recruiting NCT04797949 Phase 4 Low-dose aspirin
41 Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension: A Comparative Effectiveness Pilot Randomized Controlled Trial Active, not recruiting NCT05049616 Phase 4 ACE Inhibitors and Diuretics;NIFEdipine ER
42 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Active, not recruiting NCT04392375 Phase 4 Nifedipine 30 MG;Placebos
43 The Effectiveness of Low-dose Aspirin on Preventing Pre-eclampsia in High-risks Pregnant Women Not yet recruiting NCT04656665 Phase 4 Aspirin
44 A Prospective Randomized Clinical Research Trial Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 and Those Receiving Tdap Vaccinations at Week 36 Not yet recruiting NCT04424693 Phase 4 Tdap Vaccine Administration
45 Blood Levels of Co-inhibitory Receptors (TIM-3,LAG-3 and TIGIT)in Preeclampsia Patients Not yet recruiting NCT05294952 Phase 4
46 A Prospective Interventional Randomized Controlled Trial to Assess the Effect of Low Dose Acetylsalicylic Acid as a Preventive Treatment of Pre-eclampsia in Pregnant Women Who Underwent Frozen Embryo Transfer Not yet recruiting NCT05460416 Phase 4 Acetylsalicylic acid
47 Use of Ibuprofen Versus Dipyrone in Preeclampsia Submitted to C-section: Randomized Clinical Trial Not yet recruiting NCT05586373 Phase 4 medication 1;medication 2
48 Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT) Not yet recruiting NCT05139238 Phase 4 Labetalol;Nifedipine
49 Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial Not yet recruiting NCT05309460 Phase 4 Labetalol Oral Tablet;NIFEdipine ER
50 Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia Terminated NCT02025426 Phase 4 Phenylephrine;Ephedrine

Search NIH Clinical Center for Eclampsia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Magnesium Sulfate
Nitroglycerin

Cochrane evidence based reviews: eclampsia

Genetic Tests for Eclampsia

Genetic tests related to Eclampsia:

# Genetic test Affiliating Genes
1 Eclampsia 28

Anatomical Context for Eclampsia

Organs/tissues related to Eclampsia:

MalaCards : Kidney, Placenta, Endothelial, Liver, Heart, Brain, Lung

Publications for Eclampsia

Articles related to Eclampsia:

(show top 50) (show all 17153)
# Title Authors PMID Year
1
Correlation between maternal plasma thrombomodulin and infant birth weight in hypertensive disorders of pregnancy. 53 62
19022800 2009
2
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. 53 62
15893867 2005
3
Absence of Factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with pre-eclampsia and eclampsia. 53 62
12628278 2003
4
[Folic acid levels, homocysteine and polymorphism of methylenetetrahydrofolate reductase enzyme (MTHFR) in patients with pre-eclampsia and eclampsia]. 53 62
11268732 2001
5
Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for pre-eclampsia/eclampsia in Australian women. 53 62
10965192 2000
6
Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe. 53 62
10655155 2000
7
[Antithrombin-III in preeclampsia-eclampsia. Pilot study]. 53 62
9745197 1998
8
Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. 53 62
9531039 1998
9
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. 53 62
8960994 1996
10
HLA-G deletion polymorphism and pre-eclampsia/eclampsia. 53 62
7547760 1995
11
Pregnancy induced hypertension and antithrombin-III. 53 62
8819656 1995
12
[Antithrombin ii in eclampsia: estimation of predictive value]. 53 62
1345066 1992
13
Results of pre-eclampsia screening vary by race; cut-offs versus continuums. 62
36168771 2023
14
Effect of race on the measurement of angiogenic factors for prediction and diagnosis of pre-eclampsia. 62
36168103 2023
15
Ophthalmic artery Doppler as a marker of pre-eclampsia: Why does it work? 62
36274058 2023
16
Cardiovascular Complications During Delivery Admissions Associated With Assisted Reproductive Technology (from a National Inpatient Sample Analysis 2008 to 2019). 62
36283885 2023
17
The mechanism of action of non-coding RNAs in placental disorders. 62
36411641 2022
18
Carbohydrate quantity is more closely associated with glycaemic control than weight in pregnant women with type 1 diabetes: Insights from the Diabetes and Pre-eclampsia Intervention Trial (DAPIT). 62
35614848 2022
19
Cardiac and obstetric outcomes in pregnant patients with heart disease: a retrospective cohort study. 62
33632045 2022
20
HIV and malaria prevalence among pregnant women with and without pre-eclampsia at the Atua Government Hospital in Ghana's eastern region. 62
35514313 2022
21
A multi-institutional study of renal outcomes and renal-related pregnancy outcomes in uterus transplant recipients. 62
35822437 2022
22
Sickle cell anemia/sickle cell disease and pregnancy outcomes among ethnic tribes in India: an integrative mini-review. 62
33563075 2022
23
Should pregnant women with diabetes be counseled differently if nephropathy was detected? a population database study. 62
35337233 2022
24
Aberrant inflammation in rat pregnancy leads to cardiometabolic alterations in the offspring and intrauterine growth restriction in the F2 generation. 62
35593438 2022
25
Systematic review of pregnancy and renal outcomes for women with chronic kidney disease receiving assisted reproductive therapy. 62
36396849 2022
26
Means of reaching successful antenatal transfers to level 3 hospitals in cases of threatened very preterm deliveries: a national survey. 62
33980114 2022
27
Prevalence of maternal obesity at delivery and association with maternal and neonatal outcomes. 62
34641757 2022
28
The effect of magnesium sulfate on maternal serum electrolytes and parathyroid hormone in pre-eclampsia. 62
35656755 2022
29
Viral prevalence by gestational age and season in a large neonatal cord blood cohort. 62
34587860 2022
30
The influence of hypertensive disorders during pregnancy on the perinatal outcome of different chorionic twins. 62
34180344 2022
31
Postnatal cardiovascular morbidity following preterm pre-eclampsia: An observational study. 62
36029727 2022
32
Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome. 62
36136273 2022
33
Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia: PREPARE cohort study. 62
36474150 2022
34
Quality assessment of first-trimester screening for preterm pre-eclampsia. 62
35633510 2022
35
Attenuated effect of zinc gluconate on oxidative stress, inflammation, and angiogenic imbalance in pre-eclampsia rats. 62
36228770 2022
36
Optimising timing of steroid administration in preterm pre-eclampsia. 62
36283243 2022
37
Association between transforming growth factor-beta 1 polymorphisms and risk of pre-eclampsia: a meta-analysis. 62
35196942 2022
38
Exposure to higher concentrations of exogenous ELABELA causes HTR-8/SVneo trophoblast cell dysfunction: A possible pathogenesis of pre-eclampsia. 62
36308998 2022
39
Machine-learning-based prediction of pre-eclampsia using first-trimester maternal characteristics and biomarkers. 62
36454636 2022
40
Oxidative stress-related genes (EPHX1 and MnSOD) polymorphism and risk of pre-eclampsia: a meta-analysis. 62
33586574 2022
41
Choosing cesarean section over natural birth: Challenges of decision making among pregnant women with pre-eclampsia in Ado-Ekiti. 62
36130417 2022
42
Should all pregnant women take calcium supplements in Nepal? GRADE evidence to policy assessment. 62
36239949 2022
43
Maternal serum uric acid: a reliable prognostic indicator of foetal outcome among pre-eclamptic patients in a low resource setting. 62
34402356 2022
44
The role of miRNA-210 in pre-eclampsia development. 62
35543206 2022
45
Pre-eclampsia: incidence, determinants, and pregnancy outcomes from maternity hospitals in Qatar: a population-based case-control study. 62
34112060 2022
46
Are genetic variations in IL-1β and IL-6 cytokines associated with the risk of pre-eclampsia? Evidence from a systematic review and meta-analysis. 62
34275427 2022
47
Kaolin consumption in pregnant women: what impact on the weight of newborns? 62
34579617 2022
48
Eclampsia in Italy: A prospective population-based study (2017-2020). 62
36323063 2022
49
Elevated blood pressures during epidural placement are associated with increased risk of hypertensive disorders of pregnancy. 62
35078390 2022
50
Posterior reversible encephalopathy syndrome and autoimmunity. 62
36464226 2022

Variations for Eclampsia

Expression for Eclampsia

Search GEO for disease gene expression data for Eclampsia.

Pathways for Eclampsia

Pathways related to Eclampsia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.73 VEGFA PGF FLT1
2 10.43 VEGFA FLT1
3 10.41 VEGFA SERPINC1 FLT1
4
Show member pathways
10 VEGFA PGF FLT1

GO Terms for Eclampsia

Cellular components related to Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 VEGFA TAC3 SERPINC1 PGF PAPPA OXT
2 extracellular space GO:0005615 9.7 ACE ENG FLT1 HLA-G INHBB OXT

Biological processes related to Eclampsia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 10.08 VEGFA PGF FLT1 ENG
2 response to hypoxia GO:0001666 9.91 ACE ENG MTHFR PGF VEGFA
3 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 VEGFA PGF FLT1
4 sprouting angiogenesis GO:0002040 9.83 VEGFA PGF ENG
5 positive regulation of mast cell chemotaxis GO:0060754 9.76 VEGFA PGF
6 positive regulation of blood pressure GO:0045777 9.72 TAC3 OXT ACE
7 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.71 VEGFA ACE
8 positive regulation of systemic arterial blood pressure GO:0003084 9.67 ENG ACE
9 vascular endothelial growth factor signaling pathway GO:0038084 9.63 VEGFA PGF FLT1
10 female pregnancy GO:0007565 9.47 THBD TAC3 PGF PAPPA OXT CORIN
11 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.43 HLA-G ERAP2 ACE

Molecular functions related to Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA PGF
2 endopeptidase activity GO:0004175 9.17 PAPPA ERAP2 CORIN ACE

Sources for Eclampsia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....